{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:02:33Z","timestamp":1754020953512,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to describe patient characteristics and quantify hospital stays and outpatient visits (H&amp;OV) following diagnosis with moderate-to-severe acute graft-versus-host disease (aGVHD) in Finland and Sweden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective chart audit collected data from patient medical records of 3 specialized centers performing allogeneic hematopoietic stem cell transplantation (HSCT; Finland, <jats:italic>n<\/jats:italic>\u2009=\u20092; Sweden, <jats:italic>n<\/jats:italic>\u2009=\u20091). Eligible patients received allogeneic HSCT (January 1, 2016\u2013June 30, 2017) from any donor source, were diagnosed with grade II\u2013IV aGVHD (MAGIC or modified Glucksberg criteria) at any time from transplantation to 12\u00a0months before data collection, and were\u2009\u2265\u200918\u00a0years old at diagnosis.\u00a0Criteria for comparing patients graded with modified Glucksberg and MAGIC severity scales were defined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-five patients (Finland, <jats:italic>n<\/jats:italic>\u2009=\u200945; Sweden, <jats:italic>n<\/jats:italic>\u2009=\u200910) were included. Myeloablative conditioning was the most common conditioning regimen (81.8%); immunosuppression regimens were based on combinations of methotrexate (96.4%), in vivo T-cell depletion (80.0%), cyclosporine (63.6%), mycophenolate (40.0%), and tacrolimus (34.5%). Sixteen patients (29.1%) developed grade III\/IV aGVHD; skin was the most common organ involved (80.0%). Most patients required\u2009\u2265\u20091 hospital stay (89.1%; median of 2 hospitalizations per patient); 7 patients (14.3%) required admission to an intensive care unit. Median hospitalization duration from HSCT to discharge was 26\u00a0days. Most patients also required outpatient or emergency department visits (90.9%). Subgroup analyses showed longer hospital stays for patients receiving multiple treatment lines; no clear differences in H&amp;OV were observed between prophylactic regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Based on this retrospective study, moderate-to-severe aGVHD is associated with considerable healthcare resource utilization in Finland and Sweden, particularly in patients who received multiple lines of therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-06915-9","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T09:02:46Z","timestamp":1646211766000},"page":"5125-5135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-9306","authenticated-orcid":false,"given":"Lorenzo","family":"Sabatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Ker\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Viayna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Roset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Thunstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minja","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Nicklasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"6915_CR1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377:2167\u20132179. https:\/\/doi.org\/10.1056\/NEJMra1609337","journal-title":"N Engl J Med"},{"key":"6915_CR2","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550\u20131561. https:\/\/doi.org\/10.1016\/S0140-6736(09)60237-3","journal-title":"Lancet"},{"issue":"3","key":"6915_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21(3):389-401.e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"6915_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, EBMT Transplant Complications Working Party, EBMT\u2013NIH\u2013CIBMTR GvHD Task Force (2018) EBMT\u2013NIH\u2013CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53:1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7","journal-title":"Bone Marrow Transplant"},{"key":"6915_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4149\/neo_2012_034","volume":"59","author":"M Krejci","year":"2012","unstructured":"Krejci M, Kamelander J, Pospisil Z, Mayer J (2012) Kinetics of bilirubin and liver enzymes is useful for predicting of liver graft-versus-host disease. Neoplasma 59:264\u2013268. https:\/\/doi.org\/10.4149\/neo_2012_034","journal-title":"Neoplasma"},{"key":"6915_CR6","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3389\/fimmu.2019.02319","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Lorentino F, Nitti R, Lupo Stanghellini MT, Giglio F, Clerici D, Xue E, Lazzari L, Piemontese S, Mastaglio S, Assanelli A, Marktel S, Corti C, Bernardi M, Ciceri F, Peccatori J (2019) Interleukin-6 as biomarker for acute GvHD and survival after allogeneic transplant with post-transplant cyclophosphamide. Front Immunol 10:2319. https:\/\/doi.org\/10.3389\/fimmu.2019.02319","journal-title":"Front Immunol"},{"key":"6915_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119:296\u2013307. https:\/\/doi.org\/10.1182\/blood-2011-06-364265","journal-title":"Blood"},{"key":"6915_CR8","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socie G, Solano C, Vrhovac R, Zeiser R, Kroger N, Basak GW (2020) Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 7:e157\u2013e167. https:\/\/doi.org\/10.1016\/S2352-3026(19)30256-X","journal-title":"Lancet Haematol"},{"key":"6915_CR9","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA (2012) First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 18:1150\u20131163. https:\/\/doi.org\/10.1016\/j.bbmt.2012.04.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"6915_CR10","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","volume":"131","author":"H Major-Monfried","year":"2018","unstructured":"Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wolfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kroger N, Weber D, Chen YB, Nakamura R, Rosler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Ozbek U, Ferrara JLM, Levine JE (2018) MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 131:2846\u20132855. https:\/\/doi.org\/10.1182\/blood-2018-01-822957","journal-title":"Blood"},{"key":"6915_CR11","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.bbmt.2017.03.010","volume":"23","author":"MN Stauber","year":"2017","unstructured":"Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, Neumeister P, Greinix HT, Sill H, Sourij H, Wolfler A (2017) Early hyperglycemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease. Biol Blood Marrow Transplant 23:1186\u20131192. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"6915_CR12","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1111\/ctr.12065","volume":"27","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, Shaw BE (2013) High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III\/IV acute GvHD. Clin Transplant 27:E56-63. https:\/\/doi.org\/10.1111\/ctr.12065","journal-title":"Clin Transplant"},{"key":"6915_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbmt.2019.10.028","volume":"26","author":"J Yu","year":"2020","unstructured":"Yu J, Judy JT, Parasuraman S, Sinha M, Weisdorf D (2020) Inpatient healthcare resource utilization, costs, and mortality in adult patients with acute graft-versus-host disease, including steroid-refractory or high-risk disease, following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 26:600\u2013605. https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"6915_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","volume":"35","author":"J Yu","year":"2019","unstructured":"Yu J, Parasuraman S, Shah A, Weisdorf D (2019) Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation. Curr Med Res Opin 35:983\u2013988. https:\/\/doi.org\/10.1080\/03007995.2018.1551193","journal-title":"Curr Med Res Opin"},{"key":"6915_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1182\/blood.V128.22.1187.1187","volume":"128","author":"WW Grubb","year":"2016","unstructured":"Grubb WW, Huse S, Alam N, Dychter S, Wingard JR, Majhail NS, Berger A (2016) Economic burden of acute graft-versus-host disease (GvHD) following allogeneic hematopoietic cell transplant (HCT) for hematologic malignancies. Blood 128:1187. https:\/\/doi.org\/10.1182\/blood.V128.22.1187.1187","journal-title":"Blood"},{"key":"6915_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.tp.0000226171.43943.d3","volume":"82","author":"BM Svahn","year":"2006","unstructured":"Svahn BM, Alvin O, Ringd\u00e9n O, Gardulf A, Remberger M (2006) Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 82:147\u2013153. https:\/\/doi.org\/10.1097\/01.tp.0000226171.43943.d3","journal-title":"Transplantation"},{"key":"6915_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/bmt.2011.162","volume":"47","author":"BM Svahn","year":"2012","unstructured":"Svahn BM, Remberger M, Alvin O, Karlsson H, Ringd\u00e9n O (2012) Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant 47:706\u2013715. https:\/\/doi.org\/10.1038\/bmt.2011.162","journal-title":"Bone Marrow Transplant"},{"key":"6915_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"6915_CR19","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825\u2013828","journal-title":"Bone Marrow Transplant"},{"key":"6915_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socie G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM (1997) IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97:855\u2013864. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.1112925.x","journal-title":"Br J Haematol"},{"key":"6915_CR21","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123:3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"key":"6915_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT (2012) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120:905\u2013913. https:\/\/doi.org\/10.1182\/blood-2012-03-418202","journal-title":"Blood"},{"key":"6915_CR23","unstructured":"European Society for Blood and Marrow Transplantation. Adult acute GvHD cases in Europe between 2014\u20132018 [unpublished data available from EBMT upon request, specific fees may apply]; 2019."}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06915-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:50:03Z","timestamp":1651056603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06915-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6915"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06915-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the protocol, good pharmacoepidemiology practices, and the ethical principles embodied by the Declaration of Helsinki and applicable privacy laws. Institutional review boards\/independent ethics committees reviewed and approved the study protocol before any patients were enrolled.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This was a retrospective chart review study using de-identified patient data; therefore, no consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This was a retrospective chart review study using de-identified patient data; therefore, no consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lorenzo Sabatelli, Daniel Thunstr\u00f6m, and Minja Pfeiffer are employees and shareholders of Incyte Biosciences International. Mikko Ker\u00e4nen has provided consulting services for Novartis, Amgen, Janssen-Cilag, Pfizer, and Incyte Corporation; has an ownership interest in Iovance Biotherapeutics (IOVA); and has received honoraria from Accord Healthcare, Astellas, AbbVie, Amgen, and Takeda. Elisabet Viayna, Montserrat Roset, and Nuria Lara are employees of IQVIA Real World Solutions. Malin Nicklasson and Maija It\u00e4l\u00e4-Remes report no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Part of the results and methods of this manuscript were previously presented at Virtual ISPOR Europe 2020 (November 16\u201319, 2020).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of previous presentation"}}]}}